{
    "clinical_study": {
        "@rank": "156510", 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the long term safety and efficacy of once weekly\n      dosing of idurasulfase-beta 0.5mg/kg administered  in Hunter Syndrome(Mucopolysaccharidosis\n      II) Patients"
        }, 
        "brief_title": "The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients", 
        "completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Hunter Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Mucopolysaccharidoses", 
                "Mucopolysaccharidosis II"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have a diagnosis of Hunter syndrome(Mucopolysaccharidosis II).\n\n          -  Patients who are administered idurasulfase-beta or willing to be administered\n             idurasulfase-beta.\n\n          -  Patient's parent(s), or patient's legal guardian must have given voluntary written\n             consent to participate in the study.\n\n        Exclusion Criteria:\n\n          -  Patients who have participated in any other blind clinical trials.\n\n          -  Patient who cannot be tracked about safety.\n\n          -  Patients who are judged disqualified to participate clinical trials by investigator\n             for other causes."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hunter Syndrome(Mucopolysaccharidosis II) Patients"
            }
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044692", 
            "org_study_id": "GC1111_OS"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hunter syndrome", 
            "Mucopolysaccharidosis II", 
            "Hunterase"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "number_of_groups": "1", 
        "official_title": "The Long-term Safety of Hunterase (Idursulfase-beta) in Hunter Syndrome(Mucopolysaccharidosis II) Patients", 
        "other_outcome": [
            {
                "measure": "Percent change of urine GAG.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and every three months up to 5years."
            }, 
            {
                "measure": "Percent change of 6 minute walking test.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and every 6 months up to 5years."
            }
        ], 
        "overall_contact": {
            "email": "jindk.jin@samsung.com", 
            "last_name": "Dong-Kyu Jin"
        }, 
        "overall_official": {
            "affiliation": "Samsung medical center, Seoul, Republic of Korea", 
            "last_name": "Dong-Kyu Jin", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse event and adverse drug reaction.", 
            "safety_issue": "Yes", 
            "time_frame": "Once a week up to 5years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044692"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change of vital sign, physical and clinical examination, anti-idurasulfase-beta antibody status.", 
            "safety_issue": "Yes", 
            "time_frame": "Base line and every three months up to 5years.(exception: clinical examination-> baseline and every six months up to 5years)"
        }, 
        "source": "Green Cross Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Green Cross Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}